Conjunctival inflammation reduction

Conjunctival inflammation reduction" is not a specific molecular target or receptor. Rather, it describes a therapeutic goal—reducing inflammation in the conjunctiva, the thin membrane covering the white part of the eye and inside of the eyelids. Conjunctival inflammation occurs as part of various conditions such as allergic conjunctivitis, infectious conjunctivitis, dry eye disease, and chemosis. The inflammatory process involves multiple immune cells—including mast cells, eosinophils, dendritic cells—and mediators such as histamine, leukotrienes, cytokines (e.g., IL‑1β), prostaglandins and chemokines that drive symptoms like redness, swelling and itching[1][2][5]. Therapeutic strategies for reducing conjunctival inflammation include antihistamines to block histamine receptors on target cells; mast cell stabilizers to prevent degranulation; NSAIDs to inhibit prostaglandin synthesis via cyclooxygenase blockade; corticosteroids for broad immunosuppression in severe cases; antibiotics if bacterial infection is present; omega‑3 fatty acids for their anti-inflammatory effects in dry eye disease; vitamin D supplementation for immune modulation; and immunotherapy in select allergic cases[1][2][3][4]. No single drug targets all aspects of conjunctival inflammation due to its multifactorial nature. Because "conjunctival inflammation reduction" refers to an outcome rather than a discrete molecule or receptor classifiable by standard molecular taxonomy conventions ("receptor," "enzyme," etc.), it is not considered a canonical therapeutic target.

Histamine H1-receptor antagonism; Mast cell stabilization; Cyclooxygenase inhibition (NSAIDs)